Immune cells take on childhood cancer in early trial

NCT ID NCT02573896

Ongoing Disease control Sponsor: New Approaches to Neuroblastoma Therapy Consortium Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether giving children with relapsed neuroblastoma their own expanded natural killer (NK) cells along with the drug dinutuximab is safe and feasible. Some children may also receive lenalidomide. The study involves 13 participants aged up to 30 years and aims to find the best dose of NK cells while monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Natural killer (NK) cells, dinutuximab, and lenalidomide
What this could lead to: If successful, this could point toward a new treatment option for children with hard-to-treat neuroblastoma that has come back.
What could go wrong: This is a very early phase 1 trial with only 13 participants, so it is mainly testing safety and dosing. It may not lead to a proven treatment, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus

Atlanta, Georgia, 30322, United States
C.S Mott Children's Hospital

Ann Arbor, Michigan, 48109, United States
Children's Hospital Los Angeles

Los Angeles, California, 90027-0700, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104-4318, United States
Childrens Hospital Boston, Dana-Farber Cancer Institute.

Boston, Massachusetts, 02115, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States
Cook Children's Healthcare System

Fort Worth, Texas, 76104, United States
Nationwide Children's Hospital

Columbus, Ohio, 43205, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States
UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94115, United States
University of Chicago Comer Children's Hospital

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.